Jul 29, 2026
Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via...
Jul 29, 2026
Nate Stasko, CEO of Vast Therapeutics, is developing a novel nitric oxide-releasing therapy to treat chronic respiratory diseases, particularly fibrosis bronchiectasis, which is frequently misdiagnosed as asthma or COPD. Their lead drug candidate is a dual-mechanism therapy that is delivered to the lungs via...
Oct 25, 2017
Patients with non-cystic fibrosis bronchiectasis (NCFBE), a progressive pulmonary disease, currently have no treatment options in the US. Nancy Pecota, CFO of Aradigm Corporation, discusses NCFBE and what Aradigm is doing to help these patients and possibly others who have an un-diagnosed condition . Their inhalable...